S&P 500’s Annual Return Under Donald Trump Was 12%
The market did better only under Bill Clinton and Calvin Coolidge.
But like with any president, it’s hard to definitively credit or blame Trump for what the economy or the stock market did while he was in office. The 2017 corporate tax cuts didn’t have as large of an impact as many had expected, and didn’t result in a notable increase in business investment.
Tariffs on Chinese exports also didn’t result in the surging consumer prices that some had feared. They made imported items like washing machines temporarily more expensive and redirected some trade, but that was about it.
Anthem could benefit as the labor market recovers, says Jefferies. Dreamstime
Managed care stocks that focus on the government-funded insurance market have jumped in the week since Democrats secure control of the Senate, as investors have begun to anticipate an expansion of Obamacare, and even a public option.
Shares of Centene Corporation (CNC) are up 6.5% since the market closed on January 5, while shares of
Molina Healthcare (MOH) are up 3.6%. The
S&P 500, which is up 1.8% over the same period.
But in a note out Friday morning, Jefferies analyst David Windley argues that investors are too optimistic that the Biden administration will drive up managed care stocks in the near term by significantly expanding government-funded coverage.
Share this article
TEL AVIV, Israel and LAUSANNE, Switzerland, Jan. 14, 2021 /PRNewswire/
Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, announced that they have entered into a long-term collaboration to leverage Nucleai s artificial intelligence (AI) -powered biomarker research & discovery platform for one of Debiopharm s clinical stage oncology assets.
Having become one of Debiopharm s investment portfolio companies in 2020 (Series A), Nucleai s pathology-based platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system s spatial characteristics, creating unique and specific histological biomarkers that can predict patient response. These biomarkers allow further stratification of responder/non-responder patient populations, improve the success rate of clinical t
New state bill seeks to reduce wait times for mental health follow-up visits
FacebookTwitterEmail
State Sen. Scott Wiener has introduced legislation to require health insurance providers to help accelerate the delivery of mental health care services.Liz Hafalia / The Chronicle 2020
State Sen. Scott Wiener, D-San Francisco, introduced legislation this week that would require health insurance providers to help accelerate the delivery of mental health care services that advocates say are desperately needed to confront a growing crisis fueled by the coronavirus pandemic.
The bill, SB221, would cut down on wait times for patients seeking care for mental health and substance use issues, requiring health plans and insurers to provide timely follow-up appointments. Wiener said the legislation is meant to ensure that mental health is treated with the same urgency as other medical issues.